<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">
 <italic>INO-4800</italic> from Inovio is a DNA plasmid vaccine. The company has experience with such platforms with candidate vaccines for MERS and SARS. The vaccine needs a delivery system through electroporation, which shall add to the cost of the vaccine. Phase I trial using two doses spaced four weeks apart has been completed and results shall be available in June 2020. Inovio is planning to start phase II-III trials soon (
 <xref rid="bib81" ref-type="bibr">81</xref>).
</p>
